Abstract
Get full access to this article
View all access options for this article.
References
1.
Philippidis
A
. Novartis Confirms Deaths of 2 Patients Treated with Gene Therapy Zolgensma. Genetic Engineering & Biotechnology News August , 2022. https://www.genengnews.com/topics/genome-editing/gene-therapy/novartis-confirms-deaths-of-two-patients-treated-with-gene-therapy-zolgensma (last accessed
August 12 , 2022
).
2.
uniQure
. uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress. August 8, 2022. https://uniqure.gcs-web.com/node/10856/pdf (last accessed
August 11 , 2022
).
3.
Vertex Pharmaceuticals and Verve Therapeutics. Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease. July 20, 2022. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-verve-therapeutics-establish-collaboration-discover (last accessed
August 11 , 2022
).
4.
Frontera Therapeutics. Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities. July 19, 2022. https://www.fronteratherapeutics.com/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities (last accessed
August 11 , 2022
).
5.
MeiraGTx. MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities. August 3, 2022. https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-financing-agreement-perceptive-advisors-100 (last accessed
August 11 , 2022
).
6.
Passage Bio. Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations. August 11, 2022. https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Doses-First-Patient-in-Global-Clinical-Trial-of-PBFT02-Gene-Therapy-for-Frontotemporal-Dementia-with-Granulin-Mutations/default.aspx (last accessed
August 11 , 2022
).
7.
Sarepta Therapeutics. Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy. July 29, 2022. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-intent-submit-accelerated (last accessed
August 11 , 2022
).